akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347/ob.gyn.rep.2024.581akusherstvo-2274Research ArticleREVIEW ARTICLESНАУЧНЫЕ ОБЗОРЫThe role of ARID1A in malignant neoplasms of the female reproductive system: a modern view on diagnostic and therapeutic opportunitiesРоль ARID1A при злокачественных новообразованиях женской репродуктивной системы: современный взгляд на возможности диагностики и терапииhttps://orcid.org/0009-0001-2533-9380МарзагановаА. И.MarzaganovaA. I.

Марзаганова Ангелина Игоревна

191015 Санкт-Петербург, ул. Кирочная, д. 41

Angelina  I.  Marzaganova

41 Kirochnaya Str., Saint Petersburg 191015

marzaganovaangelina@rambler.ruhttps://orcid.org/0009-0005-1946-239XМартиросянИ. Р.MartirosyanI. R.

Мартиросян Илона Романовна 

355017 Ставрополь, ул. Мира, д. 310

Ilona R. Martirosyan

310 Mira Str., Stavropol 355017

https://orcid.org/0009-0009-2030-8479КорчемкинаА. С.KorchemkinaA. S.

Корчемкина Анастасия Сергеевна 

355017 Ставрополь, ул. Мира, д. 310

Anastasiya  S.  Korchemkina

310 Mira Str., Stavropol 355017

https://orcid.org/0009-0003-0818-5003АванесянЭ. Г.AvanesyanE. G.

Аванесян Элла Григорьевна 

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Ella G. Avanesyan

29 Nakhichevan Lane, Rostov-on-Don 344022

https://orcid.org/0009-0004-4060-4834КоркмазоваД. А.KorkmazovaD. A.

Коркмазова Джамиля Айтековна 

369001 Черкесск, Ставропольская ул., д. 36

Dzhamilia  A.  Korkmazova

36 Stavropolskaya Str., Cherkessk 369001

https://orcid.org/0009-0001-4768-9672ГрахноваО. Б.GrakhnovaO. B.

Грахнова Ольга Борисовна 

355017 Ставрополь, ул. Мира, д. 310

Olga B. Grakhnova

310 Mira Str., Stavropol 355017

https://orcid.org/0009-0001-9357-1595АкиминаВ. В.AkiminaV. V.

Акимина Виктория Викторовна 

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Victoria V. Akimina

29 Nakhichevan Lane, Rostov-on-Don 344022

https://orcid.org/0009-0001-6824-156XДжамалутдиноваА. П.DzhamalutdinovaA. P.

Джамалутдинова Аминат Пайзутдиновна 

355017 Ставрополь, ул. Мира, д. 310

Aminat P. Dzhamalutdinova

310 Mira Str., Stavropol 355017

https://orcid.org/0009-0007-3195-5175БоллоевД. А.BolloevD. A.

Боллоев Давид Аркадьевич

127006 Москва, Долгоруковская ул., д. 4

David A. Bolloev

4 Dolgorukovskaya Str., Moscow 127006

https://orcid.org/0009-0006-8930-8774ДугулубговаА. М.DugulbgovaA. M.

Дугулубгова Алина Мухамедовна

410012 Саратов, ул. Большая Казачья, д. 112

Alina M. Dugulubgova

112 Bolshaya Kazachya Str., Saratov 410012

https://orcid.org/0009-0005-8637-7128БахмудоваЗ. Г.BakhmudovaZ. G.

Бахмудова Зульмира Гасангусеновна 

410012 Саратов, ул. Большая Казачья, д. 112

Zulmira  G.  Bakhmudova

112 Bolshaya Kazachya Str., Saratov 410012

https://orcid.org/0009-0004-7761-9327СалиховаА. Т.SalikhovaA. T.

Салихова Альбина Тахировна 

450008 Уфа, ул. Ленина, д. 3 

Albina T. Salikhova

3 Lenin Str., Ufa 450008

https://orcid.org/0009-0002-6675-9098ДзигораП. А.DzigoraP. A.

Дзигора Павел Андреевич 

450008 Уфа, ул. Ленина, д. 3 

Pavel A. Dzigora

3 Lenin Str., Ufa 450008

ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской ФедерацииРоссияMechnikov North-Western State Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияStavropol State Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияRostov State Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Северо-Кавказская государственная академия»РоссияNorth Caucasus State AcademyRussian FederationФГБОУ ВО «Российский университет медицины» Министерства здравоохранения Российской ФедерацииРоссияRussian University of Medicine. Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Саратовский государственный медицинский университет имени В.И. Разумовского» Министерства здравоохранения Российской ФедерацииРоссияRazumovsky Saratov State Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Башкирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияBashkir State Medical University, Ministry of Health of the Russian FederationRussian Federation202510052025192282298Copyright © Marzaganova A.I., Martirosyan I.R., Korchemkina A.S., Avanesyan E.G., Korkmazova D.A., Grakhnova O.B., Akimina V.V., Dzhamalutdinova A.P., Bolloev D.A., Dugulbgova A.M., Bakhmudova Z.G., Salikhova A.T., Dzigora P.A., 20252025Марзаганова А.И., Мартиросян И.Р., Корчемкина А.С., Аванесян Э.Г., Коркмазова Д.А., Грахнова О.Б., Акимина В.В., Джамалутдинова А.П., Боллоев Д.А., Дугулубгова А.М., Бахмудова З.Г., Салихова А.Т., Дзигора П.А.Marzaganova A.I., Martirosyan I.R., Korchemkina A.S., Avanesyan E.G., Korkmazova D.A., Grakhnova O.B., Akimina V.V., Dzhamalutdinova A.P., Bolloev D.A., Dugulbgova A.M., Bakhmudova Z.G., Salikhova A.T., Dzigora P.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/2274

Сhromatin remodeling tumor suppressor protein ARID1A (AT-rich interaction domain 1A) is coded by the ARID1A gene that is one of the most frequently mutated genes in human oncological diseases. Inactivating mutations in the ARID1A gene have a pronounced effect on cell survival, chemoresistance, transcription and cell cycle regulation. To date, a large number of studies have focused on assessing the effect of mutations leading to loss of ARID1A function on tumor emergence, progression and therapy resistance. The high frequency of ARID1A mutations in malignant tumors of the female reproductive system opens up unique opportunities for targeted preventive and therapeutic intervention. Clear cell ovarian carcinoma and uterine body cancer bearing ARID1A mutations do not respond well to standard chemotherapy proposing no current effective targeted therapy, which underlines a need for further research in the field. ARID1A can be used as a biomarker of precancerous diseases, as well as a tool for predicting a response to radiation therapy, immunotherapy and targeted therapies. Currently, clinical trials assessing several low molecular weight and epigenetic inhibitors are being conducted in tumors of the female reproductive system with ARID1A deficiency.

Ген, который кодирует ремоделирующий хроматин белок-супрессор опухолей ARID1A (англ. AT-rich interaction domain 1A), является одним из наиболее часто мутируемых генов онкологических заболеваний человека. Инактивирующие мутации в гене ARID1A оказывают выраженное влияние на выживание клеток, химиорезистентность, транскрипцию и регуляцию клеточного цикла. На сегодняшний день большое количество исследований направлено на оценку влияния мутаций, приводящих к потере функции ARID1A, на возникновение, прогрессирование и резистентность опухоли к терапии. Высокая частота мутаций ARID1A при злокачественных опухолях женской репродуктивной системы открывает уникальные возможности для целенаправленного профилактического и терапевтического вмешательства. Светлоклеточная карцинома яичников и рак тела матки с наличием мутаций ARID1A плохо поддаются стандартной химиотерапии и на сегодняшний день не имеют эффективной таргетной терапии, что подчеркивает необходимость проведения дальнейших исследований в данной области. ARID1A может быть использован в качестве биомаркера предраковых заболеваний, а также в качестве инструмента для прогнозирования ответа на лучевую терапию, иммунотерапию и таргетные методы лечения. В настоящее время проводятся клинические испытания нескольких низкомолекулярных и эпигенетических ингибиторов при опухолях женской репродуктивной системы с дефицитом ARID1A.

рак яичниковрак эндометрияARID1Aонкогинекологиягенетикатерапияхимиотерапиялучевая терапиябиомаркерovarian cancerendometrial cancerARID1Aoncogynecologygeneticstherapychemotherapyradiation therapybiomarkerReferencesЯрмолинская М.И., Самошкин Н.Г., Полякова В.О., Нетреба Е.А. Экспрессия ARID1A, синтазы простагландина Е2 и рецептора простагландина Е2 у больных с наружным генитальным эндометриозом. Проблемы репродукции. 2019;25(3):34–9. https://doi.org/10.17116/repro20192503134.Iarmolinskaia M.I., Samoshkin N.G., Poliakova V.O., Netreba E.A. The value of the assesment of ARID1A expression, prostaglandin E2 synthase and the prostaglandin E2 receptor in patients with genital endometriosis. [Ekspressiya ARID1A, sintazy prostaglandina E2 i receptora prostaglandina E2 u bol'nyh s naruzhnym genital'nym endometriozom]. Problemy reprodukcii. 2019;25(3): 34–9. (In Russ.). https://doi.org/10.17116/repro20192503134.Воропаева Е.Н., Поспелова Т.И., Максимов В.Н. и др. Мутации в генах ARID1A и SMARCA4 при рецидивах диффузной В-крупноклеточной лимфомы с поражением ЦНС. Медицинская генетика. 2020;19(6):90–2. https://doi.org/10.25557/2073-7998.2020.06.90-92.Voropaeva E.N., Pospelova T.I., Maksimov V.N. et al. Mutations in the ARID1A and SMARCA4 genes in relapses of diffuse large B-cell lymphoma with CNS damage. [Mutacii v genah ARID1A i SMARCA4 pri recidivah diffuznoj V-krupnokletochnoj limfomy s porazheniem CNS]. Medicinskaya genetika. 2020;19(6):90–2. (In Russ.). https://doi.org/10.25557/2073-7998.2020.06.90-92.Mullen J., Kato S., Sicklick J.K., Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287. https://doi.org/10.1016/j.ctrv.2021.102287.Mullen J., Kato S., Sicklick J.K., Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287. https://doi.org/10.1016/j.ctrv.2021.102287.Heinze K., Nazeran T.M., Lee S. et al. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2022;256(4):388–401. https://doi.org/10.1002/path.5849.Heinze K., Nazeran T.M., Lee S. et al. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2022;256(4):388–401. https://doi.org/10.1002/path.5849.de Bruijn I., Kundra R., Mastrogiacomo B. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861–7. https://doi.org/10.1158/0008-5472.CAN-23-0816.de Bruijn I., Kundra R., Mastrogiacomo B. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861–7. https://doi.org/10.1158/0008-5472.CAN-23-0816.Байрамова Н.Н., Протасова А.Э., Раскин Г.А. и др. Эндометриоз-ассоциированные опухоли яичника: морфологические и иммуногистохимические особенности. Злокачественные опухоли. 2019;9(2):12–9. https://doi.org/10.18027/2224-5057-2019-9-2-12-19.Bayramova N.N., Protasova A.E., Raskin G.A. et al. Endometriosis-associated ovarian tumors: morphological and immunohistochemical features. [Endometrioz-associirovannye opuholi yaichnika: morfologicheskie i immunogistohimicheskie osobennosti]. Zlokachestvennye opuholi. 2019;9(2):12–9. (In Russ.). https://doi.org/10.18027/2224-5057-2019-9-2-12-19.Леваков С.А., Громова Т.А., Кедрова А.Г., Шешукова Н.А. Эндометриоз-ассоциированный рак яичников. Опухоли женской репродуктивной системы. 2016;12(4):47–51. https://doi.org/10.17650/1994-4098-2016-12-4-47-51.Levakov S.A., Gromova T.A., Kedrova A.G., Sheshukova N.A. Endometriosis-associated ovarian cancer. [Endometrioz-associirovannyj rak yaichnikov]. Opuholi zhenskoj reproduktivnoj sistemy. 2016;12(4):47–51. (In Russ.). https://doi.org/10.17650/1994-4098-2016-12-4-47-51.Kamori T., Oki E., Shimada Y. et al. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells. Cancer Rep. 2022;5(1):e1420. https://doi.org/10.1002/cnr2.1420.Kamori T., Oki E., Shimada Y. et al. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells. Cancer Rep. 2022;5(1):e1420. https://doi.org/10.1002/cnr2.1420.Liang H., Cheung L.W., Li J. et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22(11):2120–9. https://doi.org/10.1101/gr.137596.112.Liang H., Cheung L.W., Li J. et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22(11):2120–9. https://doi.org/10.1101/gr.137596.112.Kim Y.B., Ahn J.M., Bae W.J. et al. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916–26. https://doi.org/10.1002/ijc.32140.Kim Y.B., Ahn J.M., Bae W.J. et al. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916–26. https://doi.org/10.1002/ijc.32140.Sun D., Feng F., Teng F. et al. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency. Cell Commun Signal. 2023;21(1):48. https://doi.org/10.1186/s12964-023-01065-9.Sun D., Feng F., Teng F. et al. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency. Cell Commun Signal. 2023;21(1):48. https://doi.org/10.1186/s12964-023-01065-9.Lee S.H., Cheon J., Lee S. et al. ARID1A mutation from targeted next-generation sequencing predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract cancer. Cancer Res Treat. 2023;55(4):1291–302. https://doi.org/10.4143/crt.2022.1450.Lee S.H., Cheon J., Lee S. et al. ARID1A mutation from targeted next-generation sequencing predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract cancer. Cancer Res Treat. 2023;55(4):1291–302. https://doi.org/10.4143/crt.2022.1450.Reddy D., Bhattacharya S., Workman J.L. (mis)-Targeting of SWI/SNF complex(es) in cancer. Cancer Metastasis Rev. 2023;42(2):455–70. https://doi.org/10.1007/s10555-023-10102-5.Reddy D., Bhattacharya S., Workman J.L. (mis)-Targeting of SWI/SNF complex(es) in cancer. Cancer Metastasis Rev. 2023;42(2):455–70. https://doi.org/10.1007/s10555-023-10102-5.Chen K., Yuan J., Sia Y., Chen Z. Mechanism of action of the SWI/SNF family complexes. Nucleus. 2023;14(1):2165604. https://doi.org/10.1080/19491034.2023.2165604.Chen K., Yuan J., Sia Y., Chen Z. Mechanism of action of the SWI/SNF family complexes. Nucleus. 2023;14(1):2165604. https://doi.org/10.1080/19491034.2023.2165604.Андреева Н.А., Людовских Э.И., Коновалов Д.М. и др. SMARCA4-ассоциированные злокачественные рабдоидные опухоли: описание клинического случая и обзор литературы. Российский журнал детской гематологии и онкологии. 2022;9(2):75–84. https://doi.org/10.21682/2311-1267-2022-9-2-75-84.Andreeva N.A., Lyudovskikh E.I., Konovalov D.M. et al. SMARCA4-associated malignant rhabdoid tumors: case report and literature review. [SMARCA4-associirovannye zlokachestvennye rabdoidnye opuholi: opisanie klinicheskogo sluchaya i obzor literatury]. Rossijskij zhurnal detskoj gematologii i onkologii. 2022;9(2):75–84. (In Russ.). https://doi.org/10.21682/2311-1267-2022-9-2-75-84.Mardinian K., Adashek J.J., Botta G.P. et al. SMARCA4: Implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol Cancer Ther. 2021;20(12):2341–51. https://doi.org/10.1158/1535-7163.MCT-21-0433.Mardinian K., Adashek J.J., Botta G.P. et al. SMARCA4: Implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol Cancer Ther. 2021;20(12):2341–51. https://doi.org/10.1158/1535-7163.MCT-21-0433.Yu C., Lei X., Chen F. et al. ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nat Commun. 2022;13(1):3501. https://doi.org/10.1038/s41467-022-31197-4.Yu C., Lei X., Chen F. et al. ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nat Commun. 2022;13(1):3501. https://doi.org/10.1038/s41467-022-31197-4.Chang L., Azzolin L., Di Biagio D. et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018;563(7730):265–9. https://doi.org/10.1038/s41586-018-0658-1.Chang L., Azzolin L., Di Biagio D. et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018;563(7730):265–9. https://doi.org/10.1038/s41586-018-0658-1.Юсупова Л.Ф., Нургалиева А.Х., Хусаинова Р.И. и др. Роль генетических факторов в развитии рака желудка. Медицинская генетика. 2018;17(4):3–15. https://doi.org/10.25557/2073-7998.2018.04.3-15.Yusupova L.F., Nurgalieva A.Kh., Khusainova R.I. et al. The role of genetic factors in the development of gastric cancer. [Rol' geneticheskih faktorov v razvitii raka zheludka]. Medicinskaya genetika. 2018;17(4):3–15. (In Russ.). https://doi.org/10.25557/2073-7998.2018.04.3-15.Wang L., Qu J., Zhou N. et al. Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomed Pharmacother. 2020;130:110626. https://doi.org/10.1016/j.biopha.2020.110626.Wang L., Qu J., Zhou N. et al. Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomed Pharmacother. 2020;130:110626. https://doi.org/10.1016/j.biopha.2020.110626.Mengoli V., Ceppi I., Sanchez A. et al. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures. EMBO J. 2023;42(3):e111998. https://doi.org/10.15252/embj.2022111998.Mengoli V., Ceppi I., Sanchez A. et al. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures. EMBO J. 2023;42(3):e111998. https://doi.org/10.15252/embj.2022111998.Guan B., Wang T.-L., Shih I.-M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27. https://doi.org/10.1158/0008-5472.CAN-11-1562.Guan B., Wang T.-L., Shih I.-M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27. https://doi.org/10.1158/0008-5472.CAN-11-1562.Sun X., Wang S.C., Wei Y. et al. ARID1A has context-dependent oncogenic and tumor suppressor functions in liver cancer. Cancer Cell. 2017;32(5):574–589.e6. https://doi.org/10.1016/j.ccell.2017.10.007.Sun X., Wang S.C., Wei Y. et al. ARID1A has context-dependent oncogenic and tumor suppressor functions in liver cancer. Cancer Cell. 2017;32(5):574–589.e6. https://doi.org/10.1016/j.ccell.2017.10.007.Kamal M., Atwi D., Pang H. et al. Dedifferentiated ovarian carcinoma with ARID1A and ARID1B mutations: a clinicopathological report and literature review. Int J Surg Pathol. 2023;31(8):1526–31. https://doi.org/10.1177/10668969231157776.Kamal M., Atwi D., Pang H. et al. Dedifferentiated ovarian carcinoma with ARID1A and ARID1B mutations: a clinicopathological report and literature review. Int J Surg Pathol. 2023;31(8):1526–31. https://doi.org/10.1177/10668969231157776.Mandal J., Mandal P., Wang T.L., Shih I.M. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29(1):71. https://doi.org/10.1186/s12929-022-00856-5.Mandal J., Mandal P., Wang T.L., Shih I.M. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29(1):71. https://doi.org/10.1186/s12929-022-00856-5.Wang Y., Chen X., Qiao X. et al. Chromatin remodelling molecule ARID1A determines metastatic heterogeneity in triple-negative breast cancer by competitively binding to YAP. Cancers. 2023;15(9):2447. https://doi.org/10.3390/cancers15092447.Wang Y., Chen X., Qiao X. et al. Chromatin remodelling molecule ARID1A determines metastatic heterogeneity in triple-negative breast cancer by competitively binding to YAP. Cancers. 2023;15(9):2447. https://doi.org/10.3390/cancers15092447.Megino-Luque C., Sis? P., Mota-Martorell N. et al. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. Mol Oncol. 2022;16(11):2235–59. https://doi.org/10.1002/1878-0261.13193.Megino-Luque C., Sis? P., Mota-Martorell N. et al. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. Mol Oncol. 2022;16(11):2235–59. https://doi.org/10.1002/1878-0261.13193.Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Организация реабилитации пациенток с опухолями яичников: современные подходы и будущие направления. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(2):303–16. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.196.Blinov D.V., Solopova A.G., Achkasov E.E. et al. Strengthening rehabilitation for patients with ovarian tumors: current approaches and future directions. [Organizaciya reabilitacii pacientok s opuholyami yaichnikov: sovremennye podhody i budushchie napravleniya]. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(2):303–16. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.196.Клинические рекомендации – Рак яичников, рак маточной трубы, первичный рак брюшины – 2020-2021-2022 (31.01.2023). М.: Министерство здравоохранения Российской Федерации, 2023. 47 с. Режим доступа: http://disuria.ru/_ld/13/1326_kr20C48C56C57MZ.pdf. [Дата обращения: 15.09.2024].Clinical guidelines – Ovarian cancer, fallopian tube cancer, primary peritoneal cancer – 2020-2021-2022 (31.01.2023). [Klinicheskie rekomendacii – Rak yaichnikov, rak matochnoj truby, pervichnyj rak bryushiny – 2020-2021-2022 (31.01.2023)]. Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2023. 47 p. (In Russ.). Available at: http://disuria.ru/_ld/13/1326_kr20C48C56C57MZ.pdf. [Accessed: 15.09.2024].Новиков Ф.В., Лунева И.С., Старкова О.А. Молекулярно-генетический профиль серомуцинозных опухолей яичников. Архив патологии. 2021;83(1):53–7. https://doi.org/10.17116/patol20218301153.Novikov F.V., Luneva I.S., Starkova O.A. Molecular genetic profile of seromucinous ovarian tumors. [Molekulyarno-geneticheskij profil' seromucinoznyh opuholej yaichnikov]. Arhiv patologii. 2021;83(1):53–7. (In Russ.). https://doi.org/10.17116/patol20218301153.Katagiri A., Nakayama K., Rahman M.T. et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012;25(2):282–8. https://doi.org/10.1038/modpathol.2011.161.Katagiri A., Nakayama K., Rahman M.T. et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012;25(2):282–8. https://doi.org/10.1038/modpathol.2011.161.Kuroda T., Ogiwara H., Sasaki M. et al. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Gynecol Oncol. 2019;155(3):489–98. https://doi.org/10.1016/j.ygyno.2019.10.002.Kuroda T., Ogiwara H., Sasaki M. et al. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Gynecol Oncol. 2019;155(3):489–98. https://doi.org/10.1016/j.ygyno.2019.10.002.Clemente V., Hoshino A., Shetty M. et al. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors. Cancer Res Commun. 2022;2(8):784–94. https://doi.org/10.1158/2767-9764.crc-22-0122.Clemente V., Hoshino A., Shetty M. et al. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors. Cancer Res Commun. 2022;2(8):784–94. https://doi.org/10.1158/2767-9764.crc-22-0122.Адамян Л.В., Мартиросян Я.О., Асатурова А.В. Эндометриоз и канцерогенез яичников (обзор литературы). Проблемы репродукции. 2018;24(4):7–12. https://doi.org/10.17116/repro2018240417.Adamyan L.V., Martirosyan Ya.O., Asaturova A.V. Endometriosis and cancerogenesis of the ovaries (a review). [Endometrioz i kancerogenez yaichnikov (obzor literatury)]. Problemy reprodukcii. 2018;24(4):7–12. (In Russ.). https://doi.org/10.17116/repro2018240417.Gadducci A., Multinu F., Cosio S. et al. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021;162(3):741–50. https://doi.org/10.1016/j.ygyno.2021.06.033.Gadducci A., Multinu F., Cosio S. et al. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021;162(3):741–50. https://doi.org/10.1016/j.ygyno.2021.06.033.Адамян Л.В., Андреева Е.Н. Эндометриоз и его глобальное влияние на организм женщины. Проблемы репродукции. 2022;28(1):54–64. https://doi.org/10.17116/repro20222801154.Adamyan L.V., Andreeva E.N. Endometriosis and its global impact on a woman’s body. [Endometrioz i ego global'noe vliyanie na organizm zhenshchiny]. Problemy reprodukcii. 2022;28(1):54–64. (In Russ.). https://doi.org/10.17116/repro20222801154.Fonseca M.A.S., Haro M., Wright K.N. et al. Single-cell transcriptomic analysis of endometriosis. Nat Genet. 2023;55(2):255–67. https://doi.org/10.1038/s41588-022-01254-1.Fonseca M.A.S., Haro M., Wright K.N. et al. Single-cell transcriptomic analysis of endometriosis. Nat Genet. 2023;55(2):255–67. https://doi.org/10.1038/s41588-022-01254-1.Anglesio M.S., Papadopoulos N., Ayhan A. et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376(19):1835–48. https://doi.org/10.1056/NEJMoa1614814.Anglesio M.S., Papadopoulos N., Ayhan A. et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376(19):1835–48. https://doi.org/10.1056/NEJMoa1614814.Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2022. 252 c. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-v-rossii-v-2021-g_zabolevaemost-i-smertnost.pdf. [Дата обращения: 15.09.2024].Malignant neoplasms in Russia in 2021 (morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. [Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shahzadovoj]. Moscow, 2022. 252 p. (In Russ.). Available at: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-v-rossii-v-2021-g_zabolevaemost-i-smertnost.pdf. [Accessed: 15.09.2024].Connor E., Rose P. Management strategies for recurrent endometrial cancer. Expert Rev Anticancer Ther. 2018;18(9):873–85. https://doi.org/10.1080/14737140.2018.1491311.Connor E., Rose P. Managementstrategies for recurrent endometrial cancer. Expert Rev Anticancer Ther. 2018;18(9):873–85. https://doi.org/10.1080/14737140.2018.1491311.Свиридова Н.И., Ткаченко Л.В., Яхонтова М.А. и др. Гиперпластические процессы эндометрия: современные подходы к диагностике и лечению. Акушерство, Гинекология и Репродукция. 2024;18(1):83–95. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.464.Sviridova N.I., Tkachenko L.V., Yakhontova M.A. et al. Endometrial hyperplastic processes: modern approaches to diagnosis and treatment. [Giperplasticheskie processy endometriya: sovremennye podhody k diagnostike i lecheniyu]. Obstetrics, Gynecology and Reproduction. 2024;18(1):83–95. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.464.Li L., Yue P., Song Q. et al. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. J Pathol. 2021;253(1):119–28. https://doi.org/10.1002/path.5566.Li L., Yue P., Song Q. et al. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. J Pathol. 2021;253(1):119–28. https://doi.org/10.1002/path.5566.Asaka S., Liu Y., Yu Z.C. et al. ARID1A regulates progesterone receptor expression in early endometrial endometrioid carcinoma pathogenesis. Mod Pathol. 2023;36(2):100045. https://doi.org/10.1016/j.modpat.2022.100045.Asaka S., Liu Y., Yu Z.C. et al. ARID1A regulates progesterone receptor expression in early endometrial endometrioid carcinoma pathogenesis. Mod Pathol. 2023;36(2):100045. https://doi.org/10.1016/j.modpat.2022.100045.Matsuzaki S., Klar M., Matsuzaki S. et al. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160(2):586–601. https://doi.org/10.1016/j.ygyno.2020.10.043.Matsuzaki S., Klar M., Matsuzaki S. et al. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160(2):586–601. https://doi.org/10.1016/j.ygyno.2020.10.043.Leskela S., P?rez-Mies B., Rosa-Rosa J.M. et al. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers. 2019;11(7):964. https://doi.org/10.3390/cancers11070964.Leskela S., P?rez-Mies B., Rosa-Rosa J.M. et al. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers. 2019;11(7):964. https://doi.org/10.3390/cancers11070964.Ahmed T.B., Fedoua W., Fouad A. et al. Radiotherapy-induced uterine cacinosarcoma: A case report and review of the literature. Int J Surg Case Rep. 2022;94:106977. https://doi.org/10.1016/j.ijscr.2022.106977.Ahmed T.B., Fedoua W., Fouad A. et al. Radiotherapy-induced uterine cacinosarcoma: A case report and review of the literature. Int J Surg Case Rep. 2022;94:106977. https://doi.org/10.1016/j.ijscr.2022.106977.Кулиева Г.З., Мкртчян Л.С., Крикунова Л.И. и др. Эпидемиологические аспекты заболеваемости раком шейки матки и смертности от него (обзор литературы). Опухоли женской репродуктивной системы. 2023;19(3):77–84. https://doi.org/10.17650/1994-4098-2023-19-3-77-84.Kulieva G.Z., Mkrtchyan L.S., Krikunova L.I. et al. Epidemiological aspects of the incidence and mortality of cervical cancer (literature review). [Epidemiologicheskie aspekty zabolevaemosti rakom shejki matki i smertnosti ot nego (obzor literatury)]. Opuholi zhenskoj reproduktivnoj sistemy. 2023;19(3):77–84. (In Russ.). https://doi.org/10.17650/1994-4098-2023-19-3-77-84.Сушинская Т.В., Стуклов Н.И., Щепкина Е.В. и др. Особенности системного влияния рака шейки матки на показатели периферической крови и гемостаза в зависимости от гистологического подтипа опухоли. Опухоли женской репродуктивной системы. 2023;19(4):92–103. https://doi.org/10.17650/1994-4098-2023-19-4-92-103.Sushinskaya T.V., Stuklov N.I., Schepkina E.V. et al. Features of the systemic influence of cervical cancer on peripheral blood and hemostasis according to the tumor histological subtype. [Osobennosti sistemnogo vliyaniya raka shejki matki na pokazateli perifericheskoj krovi i gemostaza v zavisimosti ot gistologicheskogo podtipa opuholi]. Opuholi zhenskoj reproduktivnoj sistemy. 2023;19(4):92–103. (In Russ.). https://doi.org/10.17650/1994-4098-2023-19-4-92-103.Li J., Xue X., Zhang Y. et al. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma – а multi-center study in Chinese patients with uterine cervical cancer. Gynecol Oncol. 2023;175:133–41. https://doi.org/10.1016/j.ygyno.2023.05.071.Li J., Xue X., Zhang Y. et al. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma – а multi-center study in Chinese patients with uterine cervical cancer. Gynecol Oncol. 2023;175:133–41. https://doi.org/10.1016/j.ygyno.2023.05.071.Wen H., Guo Q.H., Zhou X.L. et al. Genomic profiling of Chinese cervical cancer patients reveals prevalence of DNA damage repair gene alterations and related hypoxia feature. Front Oncol. 2022;11:792003. https://doi.org/10.3389/fonc.2021.792003.Wen H., Guo Q.H., Zhou X.L. et al. Genomic profiling of Chinese cervical cancer patients reveals prevalence of DNA damage repair gene alterations and related hypoxia feature. Front Oncol. 2022;11:792003. https://doi.org/10.3389/fonc.2021.792003.Zhao J., Guo Z., Wang Q. et al. HPV infection associated DNA damage correlated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China. Cancer Manag Res. 2019;11:7197–210. https://doi.org/10.2147/CMAR.S201415.Zhao J., Guo Z., Wang Q. et al. HPV infection associated DNA damage correlated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China. Cancer Manag Res. 2019;11:7197–210. https://doi.org/10.2147/CMAR.S201415.Ruiz F.J., Sundaresan A., Zhang J. et al. Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers. 2021;13(18):4551. https://doi.org/10.3390/cancers13184551.Ruiz F.J., Sundaresan A., Zhang J. et al. Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers. 2021;13(18):4551. https://doi.org/10.3390/cancers13184551.Luo Q., Wu X., Chang W. et al. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death Differ. 2020;27(6):1981–97. https://doi.org/10.1038/s41418-019-0475-6.Luo Q., Wu X., Chang W. et al. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death Differ. 2020;27(6):1981–97. https://doi.org/10.1038/s41418-019-0475-6.Lobrano R., Manca A., Sini M.C. et al. Mammary-like adenocarcinoma of the vulva: a rare case report with next generation sequencing. Pathologica. 2023;115(2):101–6. https://doi.org/10.32074/1591-951X-848.Lobrano R., Manca A., Sini M.C. et al. Mammary-like adenocarcinoma of the vulva: a rare case report with next generation sequencing. Pathologica. 2023;115(2):101–6. https://doi.org/10.32074/1591-951X-848.Bueno D., Caniego-Casas T., S?nchez-Mart?nez M.C. et al. Vulvar pilomatrix carcinoma: morphologic and molecular features. Int J Gynecol Pathol. 2021;40(5):482–6. https://doi.org/10.1097/PGP.0000000000000726.Bueno D., Caniego-Casas T., S?nchez-Mart?nez M.C. et al. Vulvar pilomatrix carcinoma: morphologic and molecular features. Int J Gynecol Pathol. 2021;40(5):482–6. https://doi.org/10.1097/PGP.0000000000000726.Raffone A., Travaglino A., Saccone G. et al. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019;127(9):597–606. https://doi.org/10.1111/apm.12977.Raffone A., Travaglino A., Saccone G. et al. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019;127(9):597–606. https://doi.org/10.1111/apm.12977.Yokoyama Y., Matsushita Y., Shigeto T. et al. Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol. 2014;25(1):58–63. https://doi.org/10.3802/jgo.2014.25.1.58.Yokoyama Y., Matsushita Y., Shigeto T. et al. Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol. 2014;25(1):58–63. https://doi.org/10.3802/jgo.2014.25.1.58.Pasqua A.E., Sharp S.Y., Chessum N.E.A. et al. HSF1 pathway inhibitor clinical candidate (CCT361814/NXP800) developed from a phenotypic screen as a potential treatment for refractory ovarian cancer and other malignancies. J Med Chem. 2023;66(8):5907–36. https://doi.org/10.1021/acs.jmedchem.3c00156.Pasqua A.E., Sharp S.Y., Chessum N.E.A. et al. HSF1 pathway inhibitor clinical candidate (CCT361814/NXP800) developed from a phenotypic screen as a potential treatment for refractory ovarian cancer and other malignancies. J Med Chem. 2023;66(8):5907–36. https://doi.org/10.1021/acs.jmedchem.3c00156.Park Y., Chui M.H., Suryo Rahmanto Y. et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin Cancer Res. 2019;25(18):5584–94. https://doi.org/10.1158/1078-0432.CCR-18-4222.Park Y., Chui M.H., Suryo Rahmanto Y. et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin Cancer Res. 2019;25(18):5584–94. https://doi.org/10.1158/1078-0432.CCR-18-4222.Трякин А.А., Хакимова Г.Г., Заботина Т.Н. и др. Современные иммунологические биомаркеры рака толстой кишки. Злокачественные опухоли. 2018;8(4):50–8. https://doi.org/10.18027/2224-5057-2018-8-4-50-58.Tryakin A.A., Khakimova G.G., Zabotina T.N. et al. Modern views on immunological biomarkers of colon cancer. [Sovremennye immunologicheskie biomarkery raka tolstoj kishki]. Zlokachestvennye opuholi. 2018;8(4):50–8. (In Russ.). https://doi.org/10.18027/2224-5057-2018-8-4-50-58.Andrade D., Mehta M., Griffith J. et al. HuR reduces radiation-induced DNA damage by enhancing expression of ARID1A. Cancers. 2019;11(12):2014. https://doi.org/10.3390/cancers11122014.Andrade D., Mehta M., Griffith J. et al. HuR reduces radiation-induced DNA damage by enhancing expression of ARID1A. Cancers. 2019;11(12):2014. https://doi.org/10.3390/cancers11122014.Allo G., Bernardini M.Q., Wu R.C. et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 2014;27(2):255–61. https://doi.org/10.1038/modpathol.2013.144.Allo G., Bernardini M.Q., Wu R.C. et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 2014;27(2):255–61. https://doi.org/10.1038/modpathol.2013.144.Li J. Arid1a deficiency as a biomarker for sensitivity to ionizing radiation and Atr inhibition in gynecologic malignancies. Yale Medicine Thesis Digital Library, 2022. 4095 p. https://elischolar.library.yale.edu/ymtdl/4095.Li J. Arid1a deficiency as a biomarker for sensitivity to ionizing radiation and Atr inhibition in gynecologic malignancies. Yale Medicine Thesis Digital Library, 2022. 4095 p. https://elischolar.library.yale.edu/ymtdl/4095.Goel S., DeCristo M.J., McAllister S.S., Zhao J.J. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911–25. https://doi.org/10.1016/j.tcb.2018.07.002.Goel S., DeCristo M.J., McAllister S.S., Zhao J.J. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911–25. https://doi.org/10.1016/j.tcb.2018.07.002.Li Q., Jiang B., Guo J. et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discov. 2022;12(2):356–71. https://doi.org/10.1158/2159-8290.CD-20-1726.Li Q., Jiang B., Guo J. et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discov. 2022;12(2):356–71. https://doi.org/10.1158/2159-8290.CD-20-1726.Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64. https://doi.org/10.3389/fonc.2014.00064.Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64. https://doi.org/10.3389/fonc.2014.00064.Berns K., Sonnenblick A., Gennissen A. et al. Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance. Clin Cancer Res. 2016;22(21):5238–48. https://doi.org/10.1158/1078-0432.CCR-15-2996.Berns K., Sonnenblick A., Gennissen A. et al. Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance. Clin Cancer Res. 2016;22(21):5238–48. https://doi.org/10.1158/1078-0432.CCR-15-2996.Silva-Oliveira R., Pereira F.F., Petronilho S. et al. Clinical significance of ARID1A and ANXA1 in HER-2 positive breast cancer. J Clin Med. 2020;9(12):3911. https://doi.org/10.3390/jcm9123911.Silva-Oliveira R., Pereira F.F., Petronilho S. et al. Clinical significance of ARID1A and ANXA1 in HER-2 positive breast cancer. J Clin Med. 2020;9(12):3911. https://doi.org/10.3390/jcm9123911.Mo J., Ruan S., Yang B. et al. A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer. J Zhejiang Univ Sci B. 2023;24(1):64–77. https://doi.org/10.1631/jzus.B2200272.Mo J., Ruan S., Yang B. et al. A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer. J Zhejiang Univ Sci B. 2023;24(1):64–77. https://doi.org/10.1631/jzus.B2200272.Shishova A., Dyugay I., Fominykh K. et al. Enteroviruses manipulate the unfolded protein response through multifaceted deregulation of the Ire1-Xbp1 pathway. Viruses. 2022;14(11):2486. https://doi.org/10.3390/v14112486.Shishova A., Dyugay I., Fominykh K. et al. Enteroviruses manipulate the unfolded protein response through multifaceted deregulation of the Ire1-Xbp1 pathway. Viruses. 2022;14(11):2486. https://doi.org/10.3390/v14112486.Zundell J.A., Fukumoto T., Lin J. et al. Targeting the IRE1?/XBP1 endoplasmic reticulum stress response pathway in ARID1A-mutant ovarian cancers. Cancer Res. 2021;81(20):5325–35. https://doi.org/10.1158/0008-5472.CAN-21-1545.Zundell J.A., Fukumoto T., Lin J. et al. Targeting the IRE1?/XBP1 endoplasmic reticulum stress response pathway in ARID1A-mutant ovarian cancers. Cancer Res. 2021;81(20):5325–35. https://doi.org/10.1158/0008-5472.CAN-21-1545.Cheng M., Yu H., Kong Q. et al. The mitochondrial PHB2/OMA1/DELE1 pathway cooperates with endoplasmic reticulum stress to facilitate the response to chemotherapeutics in ovarian cancer. Int J Mol Sci. 2022;23(3):1320. https://doi.org/10.3390/ijms23031320.Cheng M., Yu H., Kong Q. et al. The mitochondrial PHB2/OMA1/DELE1 pathway cooperates with endoplasmic reticulum stress to facilitate the response to chemotherapeutics in ovarian cancer. Int J Mol Sci. 2022;23(3):1320. https://doi.org/10.3390/ijms23031320.Lin J., Liu H., Fukumoto T. et al. Targeting the IRE1?/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat Commun. 2021;12(1):5321. https://doi.org/10.1038/s41467-021-25684-3.Lin J., Liu H., Fukumoto T. et al. Targeting the IRE1?/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat Commun. 2021;12(1):5321. https://doi.org/10.1038/s41467-021-25684-3.Velayutham M., Cardounel A.J., Liu Z., Ilangovan G. Discovering a reliable heat-shock factor-1 inhibitor to treat human cancers: potential opportunity for phytochemists. Front Oncol. 2018;8:97. https://doi.org/10.3389/fonc.2018.00097.Velayutham M., Cardounel A.J., Liu Z., Ilangovan G. Discovering a reliable heat-shock factor-1 inhibitor to treat human cancers: potential opportunity for phytochemists. Front Oncol. 2018;8:97. https://doi.org/10.3389/fonc.2018.00097.Chakraborty A., Edkins A.L. Hop depletion reduces HSF1 levels and activity and coincides with reduced stress resilience. Biochem Biophys Res Commun. 2020;527(2):440–6. https://doi.org/10.1016/j.bbrc.2020.04.072.Chakraborty A., Edkins A.L. Hop depletion reduces HSF1 levels and activity and coincides with reduced stress resilience. Biochem Biophys Res Commun. 2020;527(2):440–6. https://doi.org/10.1016/j.bbrc.2020.04.072.Stewart J.R., Poradosu E., Woods A. et al. 8P NXP800 versus cisplatin in ARID1a-mutated ovarian clear cell carcinoma xenograft models. ESMO Open. 2023;8(1):100862. https://doi.org/10.1016/j.esmoop.2023.100862.Stewart J.R., Poradosu E., Woods A. et al. 8P NXP800 versus cisplatin in ARID1a-mutated ovarian clear cell carcinoma xenograft models. ESMO Open. 2023;8(1):100862. https://doi.org/10.1016/j.esmoop.2023.100862.Banerjee S., Stewart J., Porta N. et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int J Gynecol Cancer. 2021;31(11):1471–5. https://doi.org/10.1136/ijgc-2021-002973.Banerjee S., Stewart J., Porta N. et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int J Gynecol Cancer. 2021;31(11):1471–5. https://doi.org/10.1136/ijgc-2021-002973.Berns K., Caumanns J.J., Hijmans E.M. et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene. 2018;37(33):4611–25. https://doi.org/10.1038/s41388-018-0300-6.Berns K., Caumanns J.J., Hijmans E.M. et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene. 2018;37(33):4611–25. https://doi.org/10.1038/s41388-018-0300-6.Duska L.R., Zamarin D., Hamilton E. et al. Phase IIa study of PLX2853 in gynecologic cancers with known ARID1A mutation and phase Ib/IIa study of PLX2853/Carboplatin in platinum-resistant epithelial ovarian cancer. JCO Precis Oncol. 2023;7:e2300235. https://doi.org/10.1200/PO.23.00235.Duska L.R., Zamarin D., Hamilton E. et al. Phase IIa study of PLX2853 in gynecologic cancers with known ARID1A mutation and phase Ib/IIa study of PLX2853/Carboplatin in platinum-resistant epithelial ovarian cancer. JCO Precis Oncol. 2023;7:e2300235. https://doi.org/10.1200/PO.23.00235.Ogiwara H., Takahashi K., Sasaki M. et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35(2):177–190.e8. https://doi.org/10.1016/j.ccell.2018.12.009.Ogiwara H., Takahashi K., Sasaki M. et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35(2):177–190.e8. https://doi.org/10.1016/j.ccell.2018.12.009.Gan L., Yang Y., Li Q. et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10. https://doi.org/10.1186/s40364-018-0122-2.Gan L., Yang Y., Li Q. et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10. https://doi.org/10.1186/s40364-018-0122-2.Bitler B.G., Aird K.M., Garipov A. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231–8. https://doi.org/10.1038/nm.3799.Bitler B.G., Aird K.M., Garipov A. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231–8. https://doi.org/10.1038/nm.3799.Zheng D., Li J., Yan H. et al. Emerging roles of Aurora-A kinase in cancer therapy resistance. Acta Pharm Sin B. 2023;13(7):2826–43. https://doi.org/10.1016/j.apsb.2023.03.013.Zheng D., Li J., Yan H. et al. Emerging roles of Aurora-A kinase in cancer therapy resistance. Acta Pharm Sin B. 2023;13(7):2826–43. https://doi.org/10.1016/j.apsb.2023.03.013.Lheureux S., Tinker A., Clarke B. et al. A clinical and molecular phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the Princess Margaret Phase II Consortium. Clin Cancer Res. 2018;24(24):6168–74. https://doi.org/10.1158/1078-0432.CCR-18-1244.Lheureux S., Tinker A., Clarke B. et al. A clinical and molecular phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the Princess Margaret Phase II Consortium. Clin Cancer Res. 2018;24(24):6168–74. https://doi.org/10.1158/1078-0432.CCR-18-1244.Li J., Wang W., Zhang Y. et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020;130(5):2712–26. https://doi.org/10.1172/JCI134402.Li J., Wang W., Zhang Y. et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020;130(5):2712–26. https://doi.org/10.1172/JCI134402.Marabelle A., Fakih M., Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65. https://doi.org/10.1016/S1470-2045(20)30445-9.Marabelle A., Fakih M., Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65. https://doi.org/10.1016/S1470-2045(20)30445-9.Shen J., Ju Z., Zhao W. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556–62. https://doi.org/10.1038/s41591-018-0012-z.Shen J., Ju Z., Zhao W. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556–62. https://doi.org/10.1038/s41591-018-0012-z.Lin Y.C., Wen K.C., Sung P.L. et al. Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. J Ovarian Res. 2020;13(1):143. https://doi.org/10.1186/s13048-020-00751-3.Lin Y.C., Wen K.C., Sung P.L. et al. Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. J Ovarian Res. 2020;13(1):143. https://doi.org/10.1186/s13048-020-00751-3.Kao C.H., Liu C.T., Lin H. et al. Case report: durable response after pembrolizumab in combination with radiation – induced abscopal effect in platinum – refractory metastatic endometrial clear cell carcinoma. Front Immunol. 2022;13:1079253. https://doi.org/10.3389/fimmu.2022.1079253.Kao C.H., Liu C.T., Lin H. et al. Case report: durable response after pembrolizumab in combination with radiation – induced abscopal effect in platinum – refractory metastatic endometrial clear cell carcinoma. Front Immunol. 2022;13:1079253. https://doi.org/10.3389/fimmu.2022.1079253.Zhao M., Li W. Metabolism-associated molecular classification of uterine corpus endometrial carcinoma. Front Genet. 2023;14:955466. https://doi.org/10.3389/fgene.2023.955466.Zhao M., Li W. Metabolism-associated molecular classification of uterine corpus endometrial carcinoma. Front Genet. 2023;14:955466. https://doi.org/10.3389/fgene.2023.955466.Ji C., He Y., Wang Y. Identification of necroptosis subtypes and development of necroptosis-related risk score model for in ovarian cancer. Front Genet. 2022;13:1043870. https://doi.org/10.3389/fgene.2022.1043870.Ji C., He Y., Wang Y. Identification of necroptosis subtypes and development of necroptosis-related risk score model for in ovarian cancer. Front Genet. 2022;13:1043870. https://doi.org/10.3389/fgene.2022.1043870.Lai W., Liao J., Li X. et al. Characterization of the microenvironment in different immune-metabolism subtypes of cervical cancer with prognostic significance. Front Genet. 2023;14:1067666. https://doi.org/10.3389/fgene.2023.1067666.Lai W., Liao J., Li X. et al. Characterization of the microenvironment in different immune-metabolism subtypes of cervical cancer with prognostic significance. Front Genet. 2023;14:1067666. https://doi.org/10.3389/fgene.2023.1067666.

The authors declare that there are no conflicts of interest present.